Deliver Your News to the World

AACR, Breast Cancer Research Foundation Award Inaugural Grants in Translational Breast Cancer Research


PHILADELPHIA - Through the generous support of the Breast Cancer Research Foundation (BCRF), the American Association for Cancer Research (AACR) is pleased to announce the inaugural recipients of the 2007 BCRF-AACR Grants in Translational Breast Cancer Research. These grants provide direct support for innovative breast cancer research projects designed to accelerate the discovery, development, and application of new ways to treat breast cancer, or for preclinical research with direct therapeutic implications.

After careful evaluation and assessment by an esteemed scientific review committee, three researchers emerged as the winners of the 2007 BCRF-AACR Grants in Translational Breast Cancer Research. They are: Ingrid A. Mayer, M.D., Assistant Professor of Medicine, Vanderbilt University Medical Center; Alana Welm, Ph.D., Assistant Professor of Oncological Sciences at the Huntsman Cancer Institute, University of Utah; and Douglas Yee, M.D., Cancer Center Director and Professor, University of Minnesota-Twin Cities.

“The AACR congratulates Drs. Mayer, Welm and Yee on this outstanding achievement and applauds their efforts to translate their innovative research into potential treatments for breast cancer,” said Margaret Foti, Ph.D., M.D. (h.c.), AACR’s chief executive officer. “We are deeply grateful to the Breast Cancer Research Foundation for its commitment to cutting-edge breast cancer research and look forward to a long-lasting partnership in supporting novel translational research.”

Currently, an estimated 2 million Americans are living with or have been treated for breast cancer. Approximately 178,480 new breast cancer cases will be diagnosed this year, and about 40,460 will die from the disease. Translational research bridges the gap between laboratory research and patient care. The BCRF-AACR grant program has the vitally important goal of bringing scientific discoveries from the laboratory into breast cancer treatment protocols swiftly, safely and effectively.

Fifty-six grant applications were received and resulted in three awards, each for $233,333, to support promising research projects that could lead to individualized therapeutic options for breast cancer treatment in the near future.

Mayer’s research project, titled “Combined Endocrine and ErbB Inhibition in ER+/HER2+ Breast Cancers,” will address resistance to endocrine therapies. Through a Phase II study, she seeks to learn if the combination of an aromatase inhibitor with an EGFR/HER2 inhibitor will work better in preventing failure of tumors to respond to anti-hormonal treatment. Mayer hopes that her research will reduce mortality in patients with hormone-responsive HER2-positive breast cancer.

Welm’s research, “The MSP Pathway as a Therapeutic Target in Aggressive Breast Cancer,” will build upon her earlier studies which found that overexpression of the macrophage-stimulating protein (MSP) pathway drives progression of breast cancer. She validated the clinical relevance of this finding through gene expression data gathered from patients with early-stage breast cancer, showing that overexpression of three genes within the MSP pathway served as highly accurate indicators of poor prognosis in patients with early breast cancer. Her current research seeks to translate these findings to the clinic by developing a diagnostic test for overexpression of the MSP pathway as a biomarker for poor prognosis and to carry out preclinical tests of three MSP pathway inhibitors in order to block growth and/or metastasis of breast cancer.

Yee will look at “Gene Expression Profiling to Predict Response to anti-IGF Therapy.” This research builds upon his long-term goal of demonstrating that the insulin-like growth factor receptor (IGF1R) is an excellent target for breast cancer therapy. Yee hypothesizes that expression of specific insulin receptor substrate adaptor proteins link IGF1R to identifiable gene signatures and cancer phenotypes. To test this, Yee aims to develop gene expression profiles to predict which cancers are IGF-driven and, ultimately, which patients may best benefit from these inhibitors. His long-term goal is to use these discoveries to make the use of anti-IGF drugs more effective, and to create a better tool for making personalized therapeutic decisions for breast cancer.

Additional funding for the BCRF-AACR Grants in Translational Breast Cancer Research is generously provided by the AACR Centennial Fund, Amgen, Eli Lilly and Company, and Genentech BioOncology. To learn more about the BCRF-AACR Grants in Translational Breast Cancer Research, please visit our website.

# # #

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes nearly 26,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 70 other countries. AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care. AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.